Login
Related Links
Gene Therapy Research Institutes - US & Canada
- Center for Cell and Gene Therapy, Baylor College of Medicine, Houston
- Center for Gene Therapy, University of Michigan Medical Center, Ann Arbor
- Dep. of Gene and Cell Medicine, Mount Sinai School of Medicine, New York
- Gene Therapy Center, University of North Carolina School of Medicine
- Harvard Gene Therapy Initiative, Harvard University, Boston
- Iowa Center for Gene Therapy, University of Iowa, Iowa City
- Mayo Clinic Department of Molecular Medicine
- Mayo Graduate School, Mayo Clinic, Virology and Gene Therapy Track, Rochester
- Minnesota University, Molecular and Cellular Therapeutics Program
- Penn Vector Core, University of Pennsylvania, Philadelphia
- Powell Gene Therapy Center, University of Florida, Gainesville
Collaboration between Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital. Clinical research in the areas of stem cell transplantation, cellular therapy, and gene therapy.
The Center fosters a multidisciplinary approach to new research as well as collaborative research endeavors in the area of gene therapy. The Vector Core manufactures several recombinant viral vectors.
The research is focused on various aspects of gene therapy, such as understanding basic virology, efficient gene delivery into the nucleus of cells, and incorporation of these genes into the genome.
Research in the laboratory has centered on the molecular biology of adeno-associated virus (AAV) in order to exploit the unique features of this virus to develop an efficient viral vector system for use in human gene therapy.
The Harvard Gene Therapy Initiative is headed by Dr. Richard Mulligan with the objective of promoting the use of gene therapy and to conduct research developing new gene delivery vector technologies.
Diseases of the lung, cardiovascular system, muscles, brain, and skin are focus areas of research as well as the development of gene therapy vectors and the identification of disease-causing genes.
A multidisciplinary team of scientists and physicians work together to realize the full potential of virus, gene and cell therapies from basic science discovery to clinical translation.
Oncolytic virotherapy, gene therapy for diabetes and cardiovascular diseases, virus-based gene therapy vectors.
The program has brought together regulatory, quality, product development, manufacturing and facilities engineering expertise to enable the translation of novel, experimental research into medicine for use in human clinical trials.
Penn Vector offers a variety of services associated with the development and production of both non-viral vectors and viral vectors including those derived from adeno-associated virus (AAV), adenovirus, and lentivirus.
The primary mission is to merge molecular genetics research and health care delivery by developing new therapeutic strategies for the treatment of human diseases that involve gene transfer.
Info Research Centers
Overview of research institutes, centers and universities involved in pre-clinical and clinical gene therapy research:
Check here also the European Union Framework Programme Six (FP6) Integrated Projects, such as Attack, Clinigene, Consert and GIANT.
See also the European Union Framework Programme Seven (FP7) Integrated Projects.
Your Research Institute not listed? Click here to suggest
Like to work for a research center? Find here the perfect job in gene therapy.
US & Canada | |
Europe | |
Australia |
Check here also the European Union Framework Programme Six (FP6) Integrated Projects, such as Attack, Clinigene, Consert and GIANT.
See also the European Union Framework Programme Seven (FP7) Integrated Projects.
Your Research Institute not listed? Click here to suggest
Like to work for a research center? Find here the perfect job in gene therapy.
Gene Therapy News
- FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy - JD Supra
Fri, 29 Mar 2024 02:46:5 GMT - RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study - MD Magazine
Thu, 28 Mar 2024 23:12:1 GMT - Nanoscope targets FDA approval following positive gene therapy trial results - Longevity.Technology
Thu, 28 Mar 2024 19:17:3 GMT - Cell And Gene Therapy Manufacturing Services Market Set To Grow At A Rate Of More Than 16% Driven By Rising ... - GlobeNewswire
Thu, 28 Mar 2024 16:31:4 GMT - Cell And Gene Therapy CDMO Market Size to Reach USD 69.11 Bn by 2033 - BioSpace
Thu, 28 Mar 2024 16:06:0 GMT - Trial will test gene therapy for limb-girdle muscular dystrophy type - Muscular Dystrophy News
Thu, 28 Mar 2024 15:27:2 GMT - REGENXBIO reports promising gene therapy for eye disease By Investing.com - Investing.com
Thu, 28 Mar 2024 14:22:1 GMT - Cell therapy weekly: Clinical Trial Application Approval for Muscular Dystrophy Gene Therapy - RegMedNet
Thu, 28 Mar 2024 13:58:0 GMT - REGENXBIO and AbbVie Advance Wet AMD Gene Therapy to Phase III - Genetic Engineering & Biotechnology News
Thu, 28 Mar 2024 12:05:1 GMT - Robots and AI: The Future of Cell and Gene Therapy Manufacturing - Genetic Engineering & Biotechnology News
Wed, 27 Mar 2024 17:00:2 GMT - Gene Therapy, DNA's Past, RNA's Future: Early History - Forbes
Wed, 27 Mar 2024 16:20:5 GMT - Nanoscope Claims Phase II Win for Gene Therapy After Changing Primary Endpoint - BioSpace
Wed, 27 Mar 2024 16:18:4 GMT - Atamyo's gene therapy for LGMD2C/R5 cleared to enter clinic in Europe - BioWorld Online
Wed, 27 Mar 2024 14:00:0 GMT - Intellia ending work with Regeneron on hemophilia B gene therapy - Hemophilia News Today
Wed, 27 Mar 2024 13:35:0 GMT - Atamyo obtains clearance for muscular dystrophy gene therapy trial in Europe - Clinical Trials Arena
Wed, 27 Mar 2024 12:26:4 GMT